Zydus Cadila seeks nod for its COVID-19 vaccine ZyCoV-D, aims to produce 1 cr doses per month

Ahmedabad-based pharmaceutical firm Zydus Cadila has requested emergency use approval for its ZyCoV-D three-dose COVID shot that is the world’s first Plasmid DNA vaccine.

Zydus claims its vaccine is 66.6% effective against symptomatic COVID cases and 100% for moderate disease. It also says the vaccine is safe for children between 12 and 18 years. But its trial data is not peer-reviewed yet.

The vaccine, which is in its second phase of trials, is a “plasmid DNA” vaccine that can be stored at 2-8 degree Celsius. “We expect to produce 1 crore vaccine doses per month from August onwards and 5 crore doses by December this year. Our target is to produce 10-12 crore vaccine doses in a year", managing director of Cadila Healthcare Dr Sharvil Patel said on its Covid vaccine candidate ZyCoV-D's production.

Dr Patel has also said that a study has been carried out in more than 50 clinical sites spread across the country and during the peak of the second wave of COVID-19 between April, May and June reaffirmed the vaccine's efficacy against the new mutant strains like delta variant.

(To receive our E-paper on whatsapp daily, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

Free Press Journal